Braxia Scientific Corp
OTC:BRAXF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 5-Year Average (1.1), the stock would be worth $-0 (129% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -3.6 | $0 |
0%
|
| 5-Year Average | 1.1 | $-0 |
-129%
|
| Industry Average | 4.3 | $-0 |
-218%
|
| Country Average | 2.7 | $-0 |
-174%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
B
|
Braxia Scientific Corp
OTC:BRAXF
|
1.3m USD | -3.6 | -0.1 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
292.6B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 1 319.4 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
100.8B ZAR | 1 | 10.4 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
67.7B USD | 1 950.8 | 38 243.7 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
53B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
37.1B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
31.4B EUR | 7.8 | 173.9 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
34.4B USD | 51.6 | -3 156.8 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
29.6B ZAR | 1 | 6.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 2.7 |
| 70th Percentile | 4.9 |
| Max | 1 402.4 |
Other Multiples
Braxia Scientific Corp
Glance View
Braxia Scientific Corp. engages in the cultivation, distribution, and proliferation of artensial, medicinal mushrooms, and derivatives. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2020-02-27. The firm is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery method. The firm seeks to develop ketamine and derivatives and other psychedelic products from its Internet protocol (IP) development platform. The firm through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc. operates multidisciplinary community-based clinics offering treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal. Its treatment includes Intravenous (IV) Ketamine, Intranasal (IN) Esketamine and Oral Ketamine Tablets. Its subsidiaries include Altmed, Tassili Life Science Corp. (TLS), Artisan Growers Ltd. (AGL), Novo Formulations Ltd. (NOVO) and Canadia Rapid Treatment Centre of Excellence (CRTCE).
